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Abstract 
 
Cholesterol is a significant component of brain and is found in both 
neuronal membranes and myelin. All mammalian milks provide cholesterol 
during periods of maximal brain growth and myelination. However, infant 
formulas contain only traces of cholesterol. The purpose of this study is to 
determine if dietary cholesterol alters rat brain composition during 
development. Pregnant Long-Evans rats were randomly assigned (12/group) 
to a semi-synthetic diet with or without cholesterol. On postnatal day 1(P1), 
litters were culled to eight and weaned on P17. Litters received the same 
concentration of cholesterol as their dam from P17 to P32. On P32, pups 
were sacrificed. The left brain cortices were analyzed for cholesterol and 
protein concentration. Developing rats exposed to the cholesterol diet had an 
increase in left brain cortex size (p=0.003), cholesterol (p=0.006) and protein 
concentration (p=0.0005). Exposure to exogenous cholesterol increased brain 
cholesterol and protein concentration in developing rats. 
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Chapter 1 
Introduction 
 
Cholesterol is an abundant and important constituent of all eukaryotic 
membranes and plays a pivotal role in membrane synthesis, organization, 
dynamics, function and sorting (1-4). The adult rat brain is approximately 1% 
by weight cholesterol (5) and approximately 25% of the total body cholesterol 
in humans is found in the brain (6). Brain cholesterol is present in 
oligodendrocytes that wrap axonal regions of the neuron (in a process called 
myelination) and in plasma membranes of astrocytes and neurons (2, 6).  
Myelin is a phospholipid layer that surrounds neuronal axons and is 
important to nerve conduction. Myelin is composed of approximately 70% 
lipids and 30% proteins (2, 6). In humans, brain myelination starts in the 
second trimester of gestation and continues up to at least two years of age (6-
8) . In rats, myelination begins between 9 to 12 days and reaches a maximum 
between 15 to 20 days of life (9, 10). During this period there is a significant 
increase of cholesterol in the brain. During the maximal periods of brain 
myelination in rats, milk from the dam provides 0.78-2.07 mmol/L (30-80 
mg/dL) of cholesterol (10-12). As well, human milk provides significant 
amounts of cholesterol to human milk-fed infants during this important period 
of brain cholesterol accumulation (0.26-0.28 mmol/L or 10-11 mg/dL). In 
contrast to human milk, cow milk based formulas contain less cholesterol 
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(0.08-0.13mmol/L or 3-5mg/dL) and soy based formulas do not contain 
cholesterol (13). 
The cholesterol content in brain must be derived either from synthesis 
within the brain or from an exogenous source such as diet or maternal to 
fetal/newborn transfer (14). Animal studies using radiolabeled cholesterol 
reported that circulating cholesterol can be incorporated into the brain, 
suggesting that there is no blood-brain barrier for cholesterol (15-18). 
However, a study conducted by Morris et al demonstrated that minimal 
amounts of labeled cholesterol was supplied to 20 day suckling rat pup brains 
from exogenous sources like mothers milk (19). A study in piglets concluded 
that animals fed dietary cholesterol during the first 4 to 8 weeks of life had 
higher cholesterol concentration in cerebrum compared to piglets fed with 
diets that did not contain cholesterol (14). However, other studies suggest 
that all cholesterol in the brain is synthesized de novo (10, 20). 
In mammalian nervous systems, proteolipid protein and myelin basic 
protein constitute nearly 80% of total myelin proteins (6). Lipid and protein 
interactions play a major role in maintaining structure and function of 
biological membranes (1, 21, 22). By measuring cortex protein and 
considering the ratio of cholesterol to protein, it is possible to gain some clues 
about any effects of increasing cholesterol exposure on brain composition. 
Since cholesterol content in the brain is crucial for adequate 
myelination, neuronal growth and synaptogenesis factors that influence the 
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accumulation of cholesterol in the brain during the early development period 
of an animal are important and need to be further explored. Ultimately, the 
answer to the question could have relevance for the newborn as human milk 
contains higher amounts of cholesterol when compared to commercial 
formula milk (13). In this study, we asked if feeding dietary cholesterol to the 
rat during pregnancy and lactation and to pups after early weaning influenced 
brain cholesterol concentration.  
A rat model was chosen for this study as rats have short gestation, 
lactation and weaning periods to monitor the effect of interventions. It is not 
feasible to measure brain cholesterol in live human infants. 
 
 
Statement of purpose 
The purpose of this study was to determine if feeding cholesterol (0.5% 
by weight) to the rat during gestation and lactation and to pups at weaning 
would increase brain cortical cholesterol concentration per unit brain weight or 
per unit gram cortex protein concentration. 
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Research questions 
 
1. Will exposure to dietary cholesterol during gestation, lactation and 
after weaning increase brain cortical cholesterol in developing rats? 
 
2. Will exposure to dietary cholesterol during gestation, lactation and 
after weaning alter the brain cortical cholesterol to total protein ratio in 
developing rats?                           
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Chapter 2 
Literature Review 
 
 
Cholesterol is an abundant and important constituent of all eukaryotic 
membranes and plays a pivotal role in membrane synthesis, organization, 
dynamics, function and sorting (1-4). It was discovered by Poulletier de la 
Salle in 1769 and was named by Michel Chevreul in 1815 (23). 
Cholesterol is present in tissues and plasma lipoproteins in the form of 
free cholesterol or in combination with a long-chain fatty acid as cholesterol 
ester (24). Cholesterol is a hydrophobic molecule with a planar tetracyclic 
fused steroid ring and a flexible isooctyl hydrocarbon tail. The molecular 
formula of cholesterol is C27H46O and molecular mass is 386.65 g/mol. The 
chemical name of cholesterol is 5-cholesten-3β-ol. 
In adult humans, approximately 700 mg of cholesterol is synthesized in 
the body per day and about 300 mg per day is obtained from the diet. Egg 
yolk, butter fat, poultry, liver, shrimp and beef are the main sources of dietary 
cholesterol after weaning. In infants the main source of cholesterol is mother’s 
milk. About 10-25% of cholesterol synthesis occurs in the liver and 10% 
occurs in the intestines in humans (24). The remaining cholesterol is 
synthesized in adrenal glands, reproductive organs, brain and spinal cord. 
Cholesterol is synthesized from acetyl Co-A and HMG-Co-A reductase 
is the rate limiting enzyme in the biosynthetic pathway. Cholesterol 
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biosynthesis is regulated by dietary cholesterol that reaches the liver via 
chylomicron remnants. In tissues, cholesterol balance can be maintained 
between the factors that increase cholesterol (cholesterol synthesis, 
hydrolysis of cholesteryl ester) and those that decrease cholesterol (synthesis 
of steroid hormones, synthesis of bile acids). Cholesterol is excreted from 
liver in bile either in the form of free cholesterol or as bile acids (24). 
Total plasma cholesterol of about 200 mg/dL is considered normal.  
Cholesterol is transported to various tissues via lipoproteins of plasma. 
Lipoproteins include chylomicrons, very low density lipoproteins (VLDL), low 
density lipoproteins (LDL) and high density lipoproteins (HDL). Cholesterol 
transported via LDL is related to atherogenesis whereas that transported via 
HDL is related to protection from cardiovascular disease (24).  
Humans typically consume about 5 mg/kg/day of cholesterol through 
diet and synthesize about 10mg/kg/day (25). In mice, dietary cholesterol 
intake from synthetic cereal based animal diet is about 30mg/kg/day and 
synthesis in the body accounts for about 160 mg/kg/day (25). Total amount of 
sterol obtained from diet and de novo synthesis in the mouse is approximately 
190 mg/kg/day which is about 13 times greater than in a human (15 
mg/kg/day) (25). This is due to nearly 40 fold greater hepatic clearance of 
LDL cholesterol in mice compared to humans requiring high amounts of 
cholesterol input to maintain steady state cholesterol levels (25).  
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Cholesterol composition of the brain 
The central nervous system is composed of gray and white matter. 
White matter consists of myelin in large quantities, which surrounds axons in 
the form of myelin sheath (8).  Gray matter is made up of neuronal cell bodies 
and their dendrites (8). Magnetic resonance appearance of white matter is 
determined by the presence of myelin cholesterol (26). Adult human brain is 
composed of approximately 80% water, 10-15% lipids and the rest proteins 
(8).  
Cholesterol is a major constituent of the brain (27). Cholesterol 
comprises approximately 10% of the dry weight of the brain (8) whereas in 
other organs, cholesterol comprises about 1% of dry weight (8). About 99.5% 
of cholesterol present in the brain is unesterified (6). The majority of the 
cholesterol present in the central nervous system (CNS) is present in myelin 
sheaths and in plasma membranes of astrocytes and neurons. Myelin is 
composed of 70% lipids and 30% proteins (6, 8). Cholesterol accounts for 
27.7% of total lipids in myelin, 27.5% of total lipids in white matter and 22.0% 
of total lipids in the gray matter (8). Protein accounts for 30.0% of dry weight 
in myelin, 39% of dry weight in white matter and 55.3% of dry weight in gray 
matter (8). Other lipids in myelin include sulfatides, ehanolamine 
phosphatides, sphingomyelin, phosphatidylcholine, phosphatidylserine (8). 
Myelin contains cholesterol, phospholipids and glycosphingolipids in a ratio of 
4:4:2.  
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Origin and biosynthesis of cholesterol in brain 
Cholesterol can be provided to the brain either by endogenous 
synthesis within the brain or delivery of cholesterol via circulating lipoproteins. 
There is controversy in the literature regarding the role that circulating 
cholesterol plays in relation to supplying brain cholesterol (8). 
Couerbe first made observations in the nineteenth century that lead 
him to believe that cholesterol was the principal element of the nervous 
system (6, 28). Since then, the role of cholesterol in the nervous system 
gained importance and lead to further investigations in this area. 
Initial findings that brain cholesterol was metabolically different from 
peripheral blood cholesterol were made in 1940s (6, 29). Waelsch et al., 
showed that administration of 2H2O via drinking water to adult male rats did 
not result in incorporation of the tracer in to the unsaponifiable fraction of the 
brain lipid, i.e. cholesterol (30).  A study done on dogs demonstrated that an 
intravenous infusion of 2H-cholesterol for 3 days to a dog did not result in 
labeled cholesterol in brain and spinal cord (29). Dobbing (1963) injected rats 
with a 14C cholesterol tracer from birth to eight weeks of age and found less 
than 8% of brain sterol came from peripheral blood (17, 20). Edmond et al., 
administered 2H-cholesterol in a milk substitute to rat pups for a period of 10 
days (from 5 or 6 days of age to 15 or 16 days of age) did not find any label 
incorporated in the brain cholesterol (10).  
 
 
9
Similar studies were also done on humans. Chobanian et al., 
administered 4-14C cholesterol by intravenous injection for an average of 226 
days to terminally ill patients and did not find any traces of labeled cholesterol 
in their brains and other nervous tissue after their natural death (31). Morell 
and Jurevics in their review of literature concluded that all cholesterol 
accumulating in the brain during development was locally synthesized within 
the brain and not obtained from circulation (32). 
Other studies in rats suggest that dietary cholesterol can increase 
blood cholesterol and increase brain cholesterol by some mechanism with a 
conclusion that there is no “blood-brain barrier” for cholesterol (17, 18). A 
study in piglets by Boleman et al., showed that animals fed cholesterol during 
the first 4 to 8 weeks of life had higher cholesterol concentration in cerebrum 
compared to piglets not fed cholesterol (14). There is insufficient evidence in 
the literature to conclusively determine if exogenous source of cholesterol 
plays a role in cholesterol accumulation in the brain, especially in the early 
stages of brain development. 
The rate of synthesis and cholesterol content in the brain increases 
dramatically during brain growth and development (33-36). The rate of 
cholesterol synthesis then decreases in adulthood (6). The requirement for 
cholesterol by the nervous system is especially high during the most rapid 
periods of its myelination (32). In rats, the crucial period for accumulation of 
cholesterol in brain is the first few weeks after birth during which myelin 
 
 
10
formation takes place in the central and peripheral nervous system (32). In 
humans a crucial period is from the second trimester of gestation to two years 
of age. The question of how the brain obtains cholesterol is especially 
important in the early stages of brain development, particularly in conditions 
that lead to inadequate synthesis of cholesterol. In such circumstances, other 
means of supplying cholesterol like dietary sources should be further 
investigated (6-8). 
 
Cholesterol metabolism in the brain 
Cholesterol in the central nervous system is metabolized to 24S-
hydroxy cholesterol by the enzyme cytochrome P46 which is mainly found in 
the neurons (37). The metabolite 24S-hydroxy cholesterol can easily cross 
the blood brain barrier (37). This is the major pathway for removal of 
cholesterol from the brain and helps to maintain brain cholesterol 
homeostasis. 24S-hydroxycholesterol is subsequently converted to either bile 
acids or excreted in a sulfated or glucuronidated form into bile (37). In the 
central nervous system, cholesterol is mainly distributed in two pools, i.e. 
cholesterol in the plasma membranes of glial cells and neurons and 
cholesterol in myelin. About 0.02% of brain cholesterol in the human and 
about 0.4% in the mouse turns over each day (33). This low turnover of 
cholesterol in brain is due to efficient recycling and explains its relatively long 
half life in the brain of 4-6 months (33). This long half life decreases the 
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requirement of additional new cholesterol and may be especially important 
during periods of rapid brain growth, synaptogenesis and myelination.  
 
Functions of cholesterol in brain 
Cholesterol is an important lipid that regulates the function of neuronal 
receptors and that may thereby affect neurotransmission related to mood and 
anxiety disorders (38, 39). Cholesterol also affects membrane thickness and 
fluidity (40, 41), restricts ion leakage through membranes (42) and is involved 
in protein sorting (43) and signal transduction (44). Diaz and Monreal 
demonstrated that myelin lipids without proteins showed poor permeability to 
H+ ions (45). On the other hand, the lipid and cholesterol composition of 
membranes can affect the activity of membrane proteins. Possible 
mechanisms by which cholesterol can influence membrane proteins include 
direct binding to the proteins and activation of the proteins (8). Cholesterol 
can also interfere with the membrane proteins by altering the physical 
properties of membranes such as fluidity (8, 46) and by causing phase 
separations in the plane of membranes, thus stabilizing protein-protein 
interactions (8, 47). 
Cholesterol decreases membrane permeability and fluidity by 
compacting phospholipids and changing the order of fatty acyl chains (35). It 
is also responsible for determining the functional properties of membrane 
proteins like neurotransmitter receptors and ion channels (35). Cholesterol is 
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not evenly distributed in membranes but mostly concentrated in lipid 
microdomains or rafts (35). Lipid rafts regions of the membrane are believed 
to be involved in signal transduction, cellular functions involved in neural 
development, neurotrophic factor signaling, synaptic plasticity and axonal 
growth (48). 
Cholesterol is important for neural signal transduction and ligand 
binding in neuron transmitters. G-protein coupled receptors (GPCRs) are 
membrane proteins with seven transmembrane domains and represent one of 
the largest families of proteins in mammals (1, 49). Cells communicate with 
the external environment by signal transduction through the GCPRs. These 
receptors can be activated by various ligands including peptides, amines, 
lipids, glycoproteins and nucleotides and are important targets for the 
development of new drugs. A large number of GPCRs are present in the 
nervous system and are responsible for neuronal function. Lipid protein 
interactions play a role in the assembly, stability and function of membrane 
proteins (1, 21, 22). A cell has the capacity to vary its membrane lipid 
composition in response to stress and stimuli thereby changing the activity of 
its membrane receptors (1). Since cholesterol is an important membrane lipid, 
it has an effect on the formation and stability of membrane proteins. 
Brain cholesterol plays an important role in maintaining the structure 
and function of neuronal receptors that are very important for neural signal 
transduction. Serotonin1A is a neurotransmitter receptor from the family of 
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GPCRs and plays an important role in generating and modulating cognitive 
and behavioral functions like sleep, pain, mood, depression and anxiety (1, 
39). Serotonergic signaling plays a pivotal role in neurogenesis, 
dendritogenesis, apoptosis and axonal branching during the developmental 
stages of the brain (50). Disruption in the serotonergic system has been 
implicated in the etiology of developmental disorders like infantile autism (39). 
The role of cholesterol in modulating the ligand binding activity and G protein 
coupling of the hippocampal serotonin1A receptor was recently demonstrated 
(51). In this study, cholesterol was depleted from the hippocampal 
membranes using methyl-β-cyclodextrin (MβCD). Depletion of cholesterol 
was done using various concentrations of MβCD and it resulted in a 
concentration-dependent reduction in the binding of the specific agonist 8-
hydroxy-2 (di-N-propylamino) tetralin (8-OH-DPAT) to serotonin1A receptors. 
Cholesterol depletion also affected the G protein coupling of the receptor. 
Membranes were subsequently replenished with cholesterol using MβCD-
cholesterol complex and it resulted in recovery of ligand binding activity. This 
provides evidence that cholesterol is necessary for ligand binding and G 
protein coupling of serotonin1A. 
 
Cholesterol and brain development 
Cholesterol is required for brain myelination. Formation of myelin 
sheath around an axon or nerve fiber is called myelination. Myelin provides 
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electrical insulation to the nerve fiber and is related to the speed of nerve 
conduction (8). The function of myelin as electrical insulator is most likely due 
to the presence of lipids, including cholesterol (8). In the mammalian central 
nervous system, proteolipid protein (PLP) constitutes about 50% of the total 
myelin proteins (52). PLP is critically important for the development and 
stabilization of the myelin structure (53).  Membrane bound proteins (MBPs) 
constitute about 30% of the total protein (8). Most important function of MBPs 
is maintaining the stability and thickness of CNS myelin (8, 54, 55). Mutations 
in the transmembrane domains of these proteins may cause myelin 
deficiencies and demyelination. 
In rodents, myelination in CNS occurs predominantly during the first 
four weeks of life (56). In rats, myelination begins between 9 to 12 days and 
reaches a maximum between 15 and 20 days of life (9, 10). In humans, 
myelination begins during the second trimester of gestation and extends up to 
two years of age (6-8) at a rapid rate but continues to occur throughout 
childhood and adolescence. Myelination in the CNS is preceded by the 
accumulation of cholesterol esters, desmosterol and 7-dehydrodesmosterol 
(8, 57, 58). The high levels of these compounds may represent the 
accumulation of cholesterol for initiation of myelination (8, 59).  
Previous studies have shown that cultured neurons from mammalian 
central nervous system require cholesterol for effective synaptogenesis and 
neuronal differentiation (60-64).  The study by Goritz et al identified dendrite 
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differentiation as the rate limiting step for astrocyte induced synapse 
formation in retinal ganglion cells from postnatal rats. Moreover, they showed 
that glia derived cholesterol directly improves pre synaptic differentiation and 
continuous synaptogenesis (62). These results provide evidence that 
cholesterol is essential for growth and effective function of synapses, 
neuronal differentiation and brain development. Possible mechanism by 
which cholesterol could promote synapse formation is by serving as building 
material for synaptic membranes (35), which have been demonstrated to 
promote synaptogenesis (65). Cholesterol may also be required for synapse 
stabilization. Neurons form continuous synapses but the connections between 
these synapses may be lost if adequate cholesterol is not available (35). 
Adhesion molecules that bind the pre and post synaptic elements are mainly 
responsible for the stability of synaptic connections. These adhesion 
molecules are confined to rafts and therefore their function depends on 
cholesterol concentration and other components of the membrane such as 
spingolipids (35). Studies have also shown that cholesterol is essential for 
synaptic transmission and that accurate cholesterol homeostasis is crucial for 
synaptic plasticity (35, 66) 
Volpe et al., studied the role of cholesterol biosynthesis and the 
biosynthetic enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) 
reductase in the developing mammalian brain (67).  In this study, cells from 
the cerebral hemispheres of fetal rats of 15-16 days of gestation were 
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separated and cultured. Cholesterol biosynthesis was measured by the rate 
of incorporation of 14C-acetate into digitonin-precipitable sterols. Two peaks of 
cholesterol biosynthesis were observed, a first prominent peak after 6 days 
and a smaller one after 14 days in culture. There was a corresponding 
increase in HMG-CoA reductase enzyme activity at the same times. The 
initial prominent peak in both cholesterol biosynthesis and HMG-CoA 
reductase activity at 6 days coincided with the peaking in DNA synthesis, 
determined as the rate of incorporation of [3H]thymidine into DNA. The 
second smaller peak at 14 days coincided with the most rapid rise in the 
activity of the oligodendroglial enzyme, 2':3'-cyclic nucleotide 3'-
phosphohydrolase (CNP). These findings suggest that cholesterol 
biosynthetic pathway in developing mammalian brain is closely related to 
periods of rapid cellular proliferation and oligodendroglial differentiation. 
 
Clinical significance: Smith-Lemli-Opitz Syndrome 
Defects in cholesterol synthesis cause neurological disorder such as 
Smith-Lemli-Opitz syndrome (1, 68).  This syndrome is present from birth but 
the symptoms do not become evident until the child grows. In patients with 
Smith-Lemli-Opitz, most of the cholesterol in brain is replaced with 7-
dehydrocholesterol and is not available for myelin synthesis causing mental 
retardation in affected individuals (69, 70). This disease was first described in 
1964 as a severely fatal birth defect syndrome (71). Incidence of the disease 
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varies from 1 in 10,000 to 1 in 60,000 (72). Carrier frequency is as high as 1 
in 30 for Caucasians and lower for Asian and African populations (72). In 
Caucasians, it is the fourth common recessively inherited disorder after cystic 
fibrosis, phenylketonuria and hemochromatosis (70). 
Clinical symptoms include dysmorphic craniofacial and limb 
abnormalities like microcephaly, micrognathia, ptosis of eyelids, epicanthal 
folds, cleft palate, retroverted ears, polydactyly, and foot deformities (8, 70). 
Disorders of central and peripheral nervous system include mental 
retardation, abnormal electroencephalograms, small cerebellum, astrocyte 
proliferation, abnormal muscle tone, loss of nerve cells, absence of cerebellar 
vermis and irregular gyri. Other organs that are functionally and structurally 
affected include liver, kidneys, heart, lungs and digestive organs (8, 70). 
The biochemical defect underlying the pathogenesis is a defect in 7 
dehydroreductase an enzyme that is responsible for the conversion of 7-
dehydrodesmosterol to desmosterol and 7-dehydrocholesterol to cholesterol. 
As a result, both biochemical reactions are blocked and cholesterol is not 
synthesized. Serum cholesterol level in these patients decreases with the 
accumulation of 7-dehydrocholesterol. This appears to affect myelin synthesis 
by delaying the commencement and limiting the degree of myelination (8, 70). 
Smith-Lemli-Opitz syndrome is diagnosed by blood sterol test which 
tests for the presence of high levels of 7-dehydrocholesterol in the blood. This 
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syndrome can also be identified by an MRI (magnetic resonance imaging) 
scan which tests for physical deformities. 
A study done on Smith-Lemli-Opitz children and adolescents 
concluded that cholesterol supplementation does not improve their 
development. According to Macros et al., dietary cholesterol supplementation 
is the current available method of treatment for Smith-Lemli-Opitz syndrome 
(72). Simvastatin which inhibits the enzyme (HMG –CoA) reductase is a 
potential drug for lowering 7-dehydrocholesterol levels in Smith-Lemli-Opitz 
patients (72).  
 
Human milk and Infant formula 
Infants fed with human milk receive considerable dietary cholesterol 
(73). Human milk contains 10-11 mg/dL of cholesterol (0.26-0.28 mmol/L) 
(13). In contrast, cow milk based formulas contain less cholesterol (0.08-0.13 
mmol/L or 3-5 mg/dL) and soy based formulas do not contain cholesterol (13). 
Triacylglycerol accounts for 97% to 98% of the total lipid content in milk. Fatty 
acids constitute about 88% of total milk fat. Total fat content of human milk is 
between 30 and 50 mg/dL which provides approximately 45% to 55% of total 
energy. Human milk is also rich in essential fatty acids like linoleic acid (8-
17%), and α linolenic acid (0.5-1.0%) along with arachidonic acid (0.5-0.7%) 
and docosahexanoic acid (0.2-0.5%) (74). Sterol content in human milk varies 
from 10 to 20 mg/dL, with cholesterol being the major component (75).  
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Lammi-Keefe et al., collected milk samples from six mothers every four hours 
from 0600 hr to 2200 hr and found a diurnal pattern in the cholesterol 
concentration of milk with 8.75 mg/dL at 0600 hour and 11.2 mg/dL at 2200 
hour of the day (76). 
Boersma et al., (1991) determined cholesterol composition in 
colostrum, transitional milk and mature milk from mothers in St. Lucia (73). 
Cholesterol content was found to be 36.0 mg/dL from 0 to 4 days post 
partum, 19.7 mg/dL from 5 to 9 days and 19.0 mg/dL from 10 to 30 days. This 
suggests that cholesterol content in human milk decreases progressively over 
time. Clark and Hundrieser collected twenty five milk samples and analyzed 
for total cholesterol, total lipid and free cholesterol (77). Mean total cholesterol 
of the samples was 13.5 +/- 3.1 mg/dL and correlated with total lipid. Mean 
cholesterol was 10.9 +/- 2.3 mg/dL and correlated with total lipid. During the 
maximal periods of brain myelination in rats, mother’s milk provides 30-80 
mg/dL (0.78-2.07 mmol/L) of cholesterol (10-12). 
Finally, studies have shown that breast fed children have higher 
cognitive development compared to children who are formula fed (78-81). A 
meta-analysis done on children from infancy to adolescence showed a 3.16 
point higher cognitive score in breast fed children compared to formula fed 
children (82). Angelsen et al., demonstrated that children breast fed for longer 
duration of time showed improved cognitive development (83). However, the 
reason for this is unknown. 
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                                                      Chapter 3 
Methods 
 
Experimental design 
Female virgin Long Evans rats were purchased from Harlan Inc, 
Indianapolis. Rats were a 70 days (± 1 week) old at the start of the 
experiment and were bred to proven breeders of the same strain. Light, heat 
and humidity were kept constant for the duration of the experiment. At the 
time of initial mating, female rats were assigned randomly to nutritionally 
complete semi-synthetic diets that differed only in that one contained 
cholesterol and the other was deficient in cholesterol (see Table 1 for diet 
details). Two female rats on the same diet were housed with a proven male 
breeder and left to mate for 5 days, the duration of the estrous cycle in rats. 
On the sixth day female rats were caged separately. Their weights were 
monitored as an indication of pregnancy until they gave birth to a litter. That 
day was designated as postnatal day 0 (P0). Gestation period in rat lasts for 
21-22 days. On postnatal day 1 (P1), the litters were culled to eight and the 
remaining pups were sacrificed. 
The eight rat pups were housed with their dam until P17, at which time 
they were separated from their dam and housed two per cage. The rat pups 
continued to receive diets with the same cholesterol concentration (0.5% or 
0% by weight) as their dam. Two pups from each litter were fed with one of 
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four levels of sialic acid (see Table 2) from day 17 through day 32 to answer 
another question. However, the level of dietary sialic acid did not influence 
brain cholesterol and is not mentioned further in the report. Diet and water 
were available ad libitum. On day 32, the rats were sacrificed and the brains 
were excised and placed on dry ice until frozen solid. At that time, the sample 
was stored at -80oC. These samples were later analyzed for cholesterol 
(Infinity Cholesterol Reagent, Thermo Electron, Louisville, CO) and total 
protein (BCA Protein Assay kit, Pierce, Rockford, IL) concentration. 
 
Table 1: Composition of control and experimental group diets of dams 
 
 
 
 
 
 
 
 
 
Table 1 shows the formula for cholesterol free diet (control diet) and 
cholesterol containing diet (experimental diet) of dams. Soy bean oil was 
purchased from local grocery store and cholesterol was purchased from 
Harlan Teklad, Madison, Wisconsin. 
 
Cholesterol-Free Diet 
(0% by weight)  
 
Cholesterol-Containing Diet  
(0.5% by weight)  
 
 
Basal Diet 
 
 
Soybean oil 
 
 
Cholesterol 
 
  
 
4560 g 
 
 
350 g 
 
 
0 g 
  
 
Basal Diet 
 
 
Soybean oil 
 
 
Cholesterol 
 
4560 g 
 
 
350 g 
 
 
25 g 
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                            Composition of basal diet: (AIN 93G) 
  
Formula g/kg 
 
Basal mix 
Casein 
L-Cystine 
Corn starch 
Maltodextrin 
Sucrose 
Soybean oil 
Cellulose 
Mineral mix 
Vitamin mix 
Choline Bitartrate 
TBHQ antioxidant
 
 
 
200 
3 
397.486
132 
100 
70 
50 
35 
10 
2.5 
0.014 
 
 
                          Basal mix: Harlan Teklad TD00235 
                          Mineral mix: Harlan Teklad TD94046 (AIN 93G-MX) 
                          Vitamin mix: Harlan Teklad TD94047 (AIN 93-VX) 
 
The above table shows the formula for basal diet used by Harlan 
Teklad, Madison, Wisconsin. The basal diet was mixed with soy bean oil to 
make cholesterol free diet (control diet) and it was mixed with soy bean oil 
and cholesterol to make the cholesterol containing diet (experimental diet) 
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Table 2: Composition of control and experimental group diets with added 
levels of sialic acid 
 
Cholesterol-Free diets  Cholesterol-Containing diets  
1.Non-cholesetrol diet+sialic acid 
0 mg/kg/d  
1.Cholesterol diet+sialic acid 
0 mg/kg/d  
Basal diet 4650g Basal diet 4650g 
Soybean oil 350g Soybean oil 350g 
Casein 48.0g Cholesterol 25g 
Corn starch 8.2g Casein 48g 
  Corn starch 8.2g 
    
2.Non-cholesterol diet+sialic acid 
20 mg/kg/d  
2.Cholesterol diet+sialic acid 
20 mg/kg/d  
Basal diet 4650g Basal diet 4650g 
Soybean oil 350g Soybean oil 350g 
Glycomacropepetide 14.05g Cholesterol 25g 
Casein 36g Glycomacropeptide 14.05g 
Corn starch 6.15g Casein 36.0g 
  Corn starch 6.15g 
    
3.Non-cholesterol diet+sialic acid 
40 mg/kg/d  
3.cholestreol diet+sialic acid 
40 mg/kg/d  
Basal diet 4650g Basal diet 4650g 
Soybean oil 350g Soybean oil 350g 
Glycomacropepetide 28.1g Cholesterol 25g 
Casein 24g Glycomacropeptide 28.1g 
Corn starch 4.1g Casein 24g 
  Corn starch 4.1g 
    
4.Non-cholesterol diet+sialic acid 
80 mg/kg/d  
4.Cholesterol diet+sialic acid 
80 mg/kg/d  
Basal diet 4650g Basal diet 4650g 
Soybean oil 350g Soybean oil 350g 
Glycomacropepetide 56.2g Cholesterol 25g 
  Glycomacropeptide 56.2g 
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Table 2 shows the formula for control diet (non cholesterol fed group) 
and experimental diet (cholesterol fed group) with added levels of sialic acid. 
The basal diet mixture, cholesterol, casein and corn starch were purchased 
from Harlan Teklad, Madison, Wisconsin. Glycomacropeptide was obtained 
from Tatua co-operative Dairy Company Limited, New Zealand.  
 
Ethics 
Prior consent was obtained from The Animal Care and Use Committee 
of Kansas University Medical Center by Susan E. Carlson, PhD before 
conducting research on rats. Protocol # 2006-1585 was given by Institutional 
Animal Care and Use Committee for performing our research on rats.  
 
Sample 
A total of 86, P32 rat left brain cortices (43 non cholesterol and 43 
cholesterol samples) were analyzed for cholesterol.  Protein concentrations 
were determined on 78 samples (39 non cholesterol and 39 cholesterol 
samples) as one sample from each of the four cholesterol-sialic acid groups 
was lost. 
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Procedure 
 
Homogenation 
Animals were decapitated at 32 days of age and the brains removed 
and placed on dry ice. The samples were stored at -800C until analysis. The 
brains were thawed on ice and the left brain cortices removed, weighed and 
homogenized in an equal weight of lysis buffer (800µl of 20mM Tris HCl, 
100µl glycerol, 10µl igepal CA-630 and 10µl protease inhibitor cocktail). 
Samples were sonicated for one minute at 20% amplitude and stored at  
-80oC freezer until they were extracted. 
 
Extraction 
A 50µl aliquot of the homogenated sample was pipetted in to a 15ml 
clean glass tube (tube 1) with a 100 µl Hamilton syringe followed by the 
addition of 2.5 ml of chloroform: methanol (2:1). The sample was vortexed for 
15 minutes then centrifuged at 1500 x g for 10 minutes. The supernatant was 
transferred to a clean glass tube (tube 2) and the precipitate re-extracted with 
1ml of 2:1 chloroform: methanol by again vortexing for 10 minutes and 
centrifugation at 1500 x g for 10 minutes. The supernatant from the second 
extraction was combined with the first extraction. The solvent was vaporized 
under nitrogen, and the extracted lipids re-dissolved in 75µl of isopropanol. 
Samples were stored at -80oC freezer until analysis for cholesterol. 
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Analysis 
The cholesterol assay was performed using Infinity Cholesterol 
Reagent, Thermo Electron, Louisville, CO. 
 
Preparation of standards 
A stock cholesterol solution was prepared by dissolving 75 mg of 
cholesterol in 10 ml of isopropanol.  The stock solution was diluted with 
isopropanol as described below to make a standard curve for the cholesterol 
assay. 
 
Preparation of diluted cholesterol standards: 
 
Serial 
No 
Standards(mg/dl) Cholesterol stock(ml) Isopropanol(ml) 
1 0 0 2 
2 150 0.4 1.6 
3 300 0.8 1.2 
4 450 1.2 0.8 
5 600 1.6 0.4 
6 750 2.0 0 
 
The standards were stored at -20oC until use. 
 
To analyze the standards and samples for cholesterol, 5µl aliquots of 
each standard and sample were pipetted (using a 10 µl Hamilton syringe) in 
to a test tube. To this test tube, 500 µl of cholesterol buffer was added. The 
tubes containing the reaction mixture were then incubated in a water bath at 
37oC for five minutes. The end point of the reaction was read in a 
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spectrophotometer at 500nm. Cholesterol concentration (mg/dl) was plotted 
on the x axis and absorbance on the y axis to generate a standard curve, 
which was linear within the range of standard concentrations chosen. The 
concentration of the samples was determined from the absorbance using the 
standard curve and expressed in mg cholesterol/gram wet weight of frontal 
cortex. 
 
Principle of colorimetric assay 
The Infinity Cholesterol Reagent Kit contains cholesterol esterase, 
which will hydrolyze cholesterol esters to cholesterol and free fatty acids. 
However, brain contains almost no cholesterol esters. Cholesterol is oxidized 
to cholest-4-en-3-one and hydrogen peroxide by cholesterol oxidase. 
Hydrogen peroxide combines with hydrobenzoic acid and 4-aminoantipyrene 
to form quinoneimine dye which is responsible for the final pink color. The 
color intensity is read between 500-550 nm using an absorbance 
spectrophotometer. 
 
Protein assay 
The protein assay was performed using a BCA Protein Assay kit, 
Pierce, Rockford, IL. 
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Preparation of standards 
Standards are prepared in accordance with the instructions and 
guidelines provided with the BCA protein assay kit. Bovine serum albumin 
(BSA) is used as a standard. Each 1ml ampoule of the standard contains 2.0 
mg/ml in 0.9% saline and 0.05% sodium azide. 
 
Preparation of Diluted albumin standards: 
 
 
Vial 
 
Volume of diluent(µl) 
 
 
Volume of BSA 
 
Final concentration of 
BSA 
A 0 300µl of stock 2,000 µg/ml 
B 125 375µl of stock 1,500 µg/ml 
C 325 325µl of stock 1,000 µg/ml 
D 175 175µl from vial B 750µg/ml 
E 325 325µl from vial C 500µg/ml 
F 325 325µl from vial E 250µg/ml 
G 325 325µl from vial F 125µg/ml 
H 400 100µl from vial G 25µg/ml 
I 400 0 0µg/ml (Blank) 
 
Working range of the assay is between 125-2,000 µg/ml 
 
Sample dilution 
To analyze the total protein concentration in the frontal cortex, 10 µl of 
the original 1:1 homogenate of the frontal cortex and lysis buffer was 
combined with 990 µl of deionised water (for a 1:100 dilution) in a 2 ml 
microcentrifuge tube. The tubes were vortexed thoroughly and the samples 
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kept on ice until the samples were ready to be loaded into the micro plate 
wells. 
 
Preparation of working reagent 
The working reagent for the protein assay was prepared by mixing 50 
parts of BCA reagent A with of 1 part of reagent B. The working reagent 
remains stable for several days when stored at room temperature. BCA 
reagent A contains sodium carbonate, sodium bicarbonate, bicinchoninic 
acid, and sodium tartrate in 0.1M sodium hydroxide. BCA reagent B contains 
4% cupric sulfate 
 
Procedure for loading the micro plate 
Triplicate 10µl aliquots of all standards and samples were loaded into a 
96 well micro plate. Two hundred micro liters of working reagent was added 
to each well using a multiple pipetter. The contents of the well were mixed by 
placing the plate on a micro plate shaker for one minute. The plate was then 
incubated for 30 minutes at 370C. The absorbance was read on a micro plate 
reader at 562nm. A standard curve was plotted with protein concentration 
(mg/ml) on the x axis and absorbance on y axis. The concentration of the 
samples was determined from the standard curve in mg/ml and converted to 
mg/gram of frontal cortex after accounting for the various dilutions. 
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Principle of colorimetric analysis 
BCA protein assay kit has bicinchoninic acid for the colorimetric 
detection of total protein. Total protein present in the sample reduces Cu+2 to 
Cu+ in the presence of alkaline medium. A water soluble complex is formed 
with the chelation of two molecules of bicinchoninic acid with cuprous ion. The 
purple colored complex exhibits strong absorbance at 562nm. The 
macromolecular structure of protein, presence of amino acids like cysteine, 
cystine, tryptophan and tyrosine, and presence of peptide bonds are said to 
be responsible for the purple color formation with bicinchoninic acid. 
 
Data analysis  
Statistical analysis was carried out using Data analysis Tool Pak in 
Microsoft excel 2007. Results of the cholesterol assay, protein assay, weights 
of cortices and total body weights of rats were analyzed by one-way ANOVA. 
A p value< 0.05 was considered as statistically significant. 
Power analysis for the study was calculated based on an earlier study 
by Carlson and House, 1986 that showed an increase in total sialic acid 
content in the cerebral gangliosides of the brain (84). Based on this 
information the power for the present study is 99% with a sample size of 12 
rats per group. 
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Chapter 4 
Results 
 
We evaluated the effects of sialic acid on brain cholesterol and found 
none. No significant difference was found for level and level of sialic acid by 
cholesterol interaction. As a result, statistical analysis was done by one-way 
ANOVA for cholesterol intake. 
The mean body weight of control group (non cholesterol fed) and 
experimental group (cholesterol fed) rats on day 17 was not significantly 
different (Table 3). SD is standard deviation, SE is standard error. 
 
 
Table 3. P17 mean rat weights, control (non cholesterol) versus experimental 
group (cholesterol) 
 
 
 
 
Sample 
Group 
 
 
Mean 
weight(g) 
      SD SE n p value 
 
Non 
Cholesterol 
 
39.73 4.65 0.71 43 
0.33  
 
Cholesterol 
 
 
40.68 4.37 0.66 43 
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The mean body weight of control group (non cholesterol fed) and 
experimental group (cholesterol fed) rats on day 32 was not significantly 
different (Table 4). 
 
Table 4. P32 mean rat weights, control (non cholesterol) versus 
experimental group (cholesterol) 
 
 
Sample 
Group 
 
Mean 
weight(g) SD SE n 
p 
value 
 
Non 
Cholesterol 
 
106.13 10.92 1.66 43 
0.808  
 
Cholesterol 
 
 
105.55 11.24 1.71 43 
 
 
  
 
 
 
 
 
 
 
33
The mean cortex weight of control group (non cholesterol fed) and 
experimental group (cholesterol fed) of P32 rats was not significantly different 
(Table 5). 
 
Table 5. Mean cortex weights of P32 rat brains, control (non cholesterol) 
versus experimental (cholesterol) group 
 
 
 
Sample 
Group 
 
Mean 
weight(g) SD SE n p value 
 
Non 
Cholesterol 
 
0.580 0.054 0.0083 43 
0.33  
 
Cholesterol 
 
 
0.592 0.069 0.0105 43 
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The mean right cortex weight of control group (non cholesterol fed) and 
experimental group (cholesterol fed) of P32 rats was not significantly different 
(Table 6).  
 
Table 6. P32 mean right cortex weights, control (non cholesterol) versus 
experimental (cholesterol) group 
 
 
Sample 
Group 
 
Mean 
weight(g) SD SE n p value 
 
Non 
Cholesterol 
 
0.287 0.044 0.0067 43 
0.575  
 
Cholesterol 
 
 
0.281 0.055 0.0084 43 
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The mean left cortex weight of experimental group (cholesterol fed) 
was significantly higher than the control group (non cholesterol fed) of P32 
rats (Table 7).  
 
Table 7. P32 mean left cortex weights, control (non cholesterol) versus 
experimental (cholesterol) group 
 
 
Sample 
Group 
 
Mean 
weight(g) SD SE n p value 
 
Non 
Cholesterol 
 
0.292 0.032 0.005 43 
0.0039**  
 
Cholesterol 
 
 
0.311 0.026 0.004 43 
 
** p value highly significant 
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 The mean cholesterol concentration (mg/g) of left brain cortex in 
experimental group (cholesterol fed) was significantly higher than the control 
group (non cholesterol fed) of P32 rats (Table 8).  
 
Table 8. Mean cholesterol concentration of P32 rat brain left cortices, control 
group (non cholesterol) versus experimental group (cholesterol) 
 
 
Sample 
Group 
 
Cholesterol 
conc. (mg/g) SD SE n p value 
 
Non 
Cholesterol 
 
11.71 1.336 0.203 43 
0.006**  
 
Cholesterol 
 
 
12.606 1.62 0.247 43 
 
** p value highly significant 
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Figure 1: P32 Rat Brain Left Cortex Cholesterol Concentration 
 
 
     
 
    Figure 1 displays the cholesterol concentration of control (non cholesterol) 
and experimental (cholesterol) group rats analyzed on P32. Mean cholesterol 
concentration of control group rats is 11.71 mg/g and experimental group rats 
is 12.606 mg/g respectively. The two standard error bars shown in the figure 
do not overlap indicating that the two means are statistically significant. 
P<0.01 indicates that it is highly significant. 
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The mean total protein concentration (mg/g) of left brain cortex in 
experimental group (cholesterol fed) was significantly higher that the control 
group (non cholesterol fed) of P32 rats (Table 9).  
 
Table 9. Mean total protein concentration in P32 rat brain left cortices, control 
group (non cholesterol) versus experimental group (cholesterol) 
 
 
Sample 
Group 
 
Protein 
conc.(mg/g) SD SE n p value 
 
Non 
Cholesterol 
 
50.2 4.82 0.772 39 
0.0005**  
 
Cholesterol 
 
 
53.7 3.68 0.589 39 
 
** p value highly significant 
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          Figure 2: P32 Rat Brain Left Cortex Total Protein Concentration 
 
 
 
 
 Figure 2 displays the total protein concentration of control (non 
cholesterol) and experimental (cholesterol) group rats analyzed on P32. Mean 
total protein concentration of control group rats is 50.2 mg/g and experimental 
group rats are 53.7 mg/g respectively. The two standard error bars shown in 
the figure do not overlap indicating that the two means are statistically 
significant. P<0.01 indicates that it is highly significant. 
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The cholesterol to total protein ratio in left brain cortex in control group 
(non cholesterol fed) and experimental group (cholesterol fed) of P32 rats 
was not significantly different (Table 10).  
 
Table 10. Cholesterol to total protein ratio for P32 rat brain left cortices, 
control group (non cholesterol) versus experimental group (cholesterol) 
 
 
Sample 
Group 
 
Protein 
conc.(mg/g) SD SE n p value 
 
Non 
Cholesterol 
 
0.235 0.033 0.005 39 
0.75  
 
Cholesterol 
 
 
0.237 0.025 0.004 39 
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                                                      Chapter 5 
Discussion 
 
The purpose of this study was to determine if feeding cholesterol (0.5% 
by weight) to the rat during gestation and lactation and to pups at weaning will 
increase brain cortical composition of cholesterol and influence the 
cholesterol to total protein ratio in the brain. The results showed that dietary 
cholesterol significantly increased brain cortical cholesterol and protein 
concentration in developing rats when compared to rats fed with no 
cholesterol diet. The ratio of cholesterol to total protein remained unchanged. 
Surprisingly, the left cortex weight was significantly higher in the cholesterol 
fed rats. 
Previous studies showed that radioactive dietary cholesterol 
administered to rat pups for a 10 day period from 5 or 6 days to 15 or 16 days 
of age via milk substitutes did not result in incorporation of labeled cholesterol 
in the brain (10). However, a study conducted by Morris et a.,l demonstrated 
that minimal amounts of labeled cholesterol was supplied to 20 day suckling 
rat pup brains from exogenous sources like mothers milk (19). Haque and 
Mozaffor (1992) demonstrated a 10% increase of brain myelin cholesterol in 
20 day old suckling mice pups whose dams were fed with ten times the 
weight of cholesterol used in our study or 5% dietary cholesterol compared to 
controls (85). This study implies that supplemental cholesterol fed to the 
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dams increased cholesterol concentration in dams’ milk thereby increasing 
the amount of dietary cholesterol available to the pups. A study by 
Schoknecht et al., demonstrated that dietary supplementation of cholesterol 
(200 mg/100 g diet for 35 days) increased cerebral brain cholesterol in pigs 
(86). A study in piglets showed that animals fed with dietary cholesterol during 
the first 4 to 8 weeks of life had higher cholesterol concentration in cerebrum 
compared to piglets fed with diets that did not contain cholesterol (14). Ours is 
the first study in rats to show that feeding dietary cholesterol to rats at 
gestation, lactation and weaning increased brain cortical cholesterol 
concentration significantly. 
Brain can synthesize cholesterol de novo (10, 20). Morell and Jurevics 
postulated that cholesterol accumulating in the brain during development is 
locally synthesized within the brain and found no evidence of a contribution 
from the circulation (32). However, there were also a few studies that reported 
that dietary cholesterol can increase blood cholesterol and that blood 
cholesterol can be incorporated into the brain, suggesting that a tight blood 
brain barrier may not exist for cholesterol (17, 18). Our study has 
demonstrated that dietary cholesterol can increase brain cortical cholesterol. 
This suggests that exogenous source of cholesterol can contribute to 
accumulated cholesterol in the brain during early developmental stages by 
some mechanism. 
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A secondary research question was how dietary cholesterol might 
influence the ratio of cholesterol to total protein in left brain cortex of 
developing rats. In mammalian nervous systems, proteolipid protein and 
myelin basic protein constitute nearly 80% of total myelin proteins (6). Lipid-
protein interactions play a major role in maintaining structure and function of 
biological membranes, regulation and dysfunction of brain cholesterol (1). It is 
also important to see how dietary changes influence total protein 
concentration and thus cholesterol to total protein ratio in the brain. Our study 
showed that dietary cholesterol supplementation to the rat during gestation, 
lactation and to pups at weaning increased the left cortex brain composition of 
total protein with no change in the cholesterol to total protein ratio indicating 
that there was a proportionate increase in cholesterol and total protein. This 
may mean that an increase in brain cortical cholesterol caused an adequate 
and proportionate increase in the composition of membrane proteins. Such 
maintenance of physiological cholesterol to protein ratio is important as lipid 
function is closely interrelated to protein in myelin and cell membranes.  
Although there was no significant difference in overall brain weight 
between the two groups, left brain cortex weight was significantly higher in the 
cholesterol fed group when compared to the non-cholesterol group with no 
difference seen in right brain cortex weights. While an increase in cortical 
weight can be explained by the proportionate increase in cholesterol and total 
protein content, it is unclear why the weight increase is limited to the left 
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cortex. A study on piglets fed with cholesterol rich diet showed a significant 
increase in cerebrum weight when compared to the group fed with non-
cholesterol diet (14). However, separate measurements of left and right 
cortices were not done in that study. Further investigations may be needed to 
elucidate the above findings from our study. 
An increase in left cortex weight and brain cholesterol and total protein 
content may theoretically be explained by a relatively higher weight gain in 
cholesterol fed rats. We measured the weights of all cholesterol and non 
cholesterol fed rats at P17 and P32 and there was no significant difference in 
weight between the two groups. Therefore, results from our study cannot be 
explained by differences in dietary uptake or weight gain in the two groups. 
Previous studies also did not show increase in body weights of rats fed with 
cholesterol (10). 
In neonates, cell membrane synthesis, myelin formation and 
synaptogenesis are the most important functions of cholesterol in the central 
nervous system. Studies in preterm infants have demonstrated that breast 
milk fed infants may have better developmental outcomes and higher 
intelligent quotients than infants fed with formula milk (87, 88). Human milk 
has higher amounts of cholesterol than formula milk (13) and since we have 
demonstrated that dietary cholesterol can increase brain cortical cholesterol, 
there is a possibility that exogenous cholesterol might be making a significant 
impact on the neurological development of the brain.  
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Haque and Mozaffar conducted a study that showed the effect of 
dietary cholesterol on myelination of mouse brain (85). In their study, 20 day 
suckling pups whose dams were fed with 5% cholesterol showed a 10% 
higher myelin cholesterol compared to the control group. This data suggests 
that dietary cholesterol fed to the dams during gestation altered brain 
myelination of weaning mice. Since cholesterol plays a very important role in 
signal transduction and ligand binding activities of myelin proteins, insufficient 
amounts of cholesterol can interrupt these activities including myelin 
formation. Inadequate synthesis of myelin may in turn result in disruption of 
cognitive function, loss of memory and speech impairment. Since maximum 
myelin formation takes place during early developmental stages, it becomes 
important to provide infants with sufficient cholesterol to supplement de novo 
synthesis. 
Increase in brain cholesterol and protein content may affect the 
cognitive function, nervous function and behavior of rats. These effects were 
not studied in our current study. Therefore, further investigations are needed 
to see if increase in brain cholesterol has any affect on the physiology of 
nervous system and behavior. 
In our study, exogenous cholesterol increased cortical cholesterol and 
total protein concentration as discussed earlier. A proportionate increase in 
cholesterol and total protein in the left cortex along with the increase in left 
brain cortex weight suggests that there was an increase in overall 
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neurogenesis or synaptogenesis with dietary cholesterol. Another possibility 
given that final 1:4 ratio of cholesterol to protein is that the increase occurred 
in white matter. Previous studies have shown that cultured CNS neurons from 
mammalian nervous system require cholesterol for effective synaptogenesis 
and neuronal differentiation and addition of cholesterol to cultured CNS 
neurons increased the number of synapses formed (60-64). CNS myelination 
and synaptogenesis require cholesterol, which in turn are rate limiting factors 
for brain maturation. These studies provide evidence that cholesterol is 
required for normal brain development. Our results suggest that dietary intake 
of cholesterol during initial periods of brain development increase cholesterol 
content in the brain, which has implications for neuronal development, 
myelination, synapse formation and infant feeding. 
 
Implications 
Since the mean brain cholesterol concentration of the cholesterol fed 
rat group is higher than the control group, it provides evidence that an 
external source of cholesterol from the time of conception to 32 days of age in 
the rat can increase brain cholesterol accumulation. This can lead to studies 
focusing on the behavior of rats fed with cholesterol or not to determine if 
cholesterol fed rats demonstrate some different behaviors compared to rats 
not fed with cholesterol. Such evidence would also suggest that human 
infants fed human milk might also have higher brain cholesterol than infants 
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fed formulas (which are low in cholesterol) and could lead to studies of 
cholesterol supplementation and behavior in human infants 
 
Limitations 
Animal studies may not accurately reflect human metabolism. For 
example, mouse studies have shown that total amount of sterol obtained from 
diet and de novo synthesis is approximately 190 mg/kg/day, which is about 13 
times greater than that in humans (15 mg/kg/day) (25). Metabolic pathways, 
membrane composition, developmental stages and maturation at birth may 
not be exactly similar in rats and humans (89). However, an animal 
experimental study is the first step towards an investigation like this as it 
involves procedures that are not feasible in humans. 
Analysis of cholesterol and total protein content in the right cortex was 
not measured in this study because that portion of the cortex was used for 
analysis of brain gangliosides. Analysis of cholesterol content was attempted 
on rat milk consumed by pups at P1. However, it could not be accurately 
measured due to interference of stomach contents, acid and mucus.  
Although brain cholesterol was increased by dietary cholesterol, we 
could not determine when dietary cholesterol exposure produced the effect as 
cholesterol exposure was increased through gestation, nursing and after 
weaning. 
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Future studies 
Since the results of this rat study showed that feeding 0.5% cholesterol 
during gestation, lactation and to pups at weaning increased cholesterol and 
total protein concentrations in left brain cortices, studies focusing on the 
behavior of rats fed with and without cholesterol should be carried out to see 
if the two groups demonstrate different behaviors.  
Our study has shown an increase in left brain cortex weight in the 
cholesterol fed rat group. Studies are needed to evaluate the disparity in 
weight gain between the right and left cortices. Also, studies evaluating the 
effect of increasing amounts of cholesterol in rat diets can be done. 
Finally, infants fed human milk might accumulate higher brain 
cholesterol than infants fed formulas (which are low in cholesterol) and could 
lead to studies of cholesterol supplementation and behavior in human infants. 
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                                                      Chapter 6 
Summary 
 
Cholesterol is a significant component of brain. In humans about 25% 
of total body cholesterol is present in brain. Cholesterol content in the brain is 
crucial for adequate myelination, synaptogenesis and neuronal function. All 
mammalian milks, including human milk, provide cholesterol during periods of 
maximal brain myelination. However, US infant formulas contain only traces 
of cholesterol. This study examined the effect of dietary cholesterol on brain 
cholesterol and total brain protein in developing rats. Pregnant Long-Evans 
rats were randomly assigned to a nutritionally complete semi-synthetic diet 
(AIN-93G) with or without cholesterol (0.5% by weight or none). Litters were 
culled to eight on postnatal day one and weaned on day 17. Two pups from 
each litter received the same concentration of cholesterol as their dam at one 
of four levels of sialic acid (0, 20, 40, 80 mg/kg/day) from P17 to P32. On 
P32, rat pups were sacrificed. The left brain cortices were extracted and 
analyzed for cholesterol and total protein. Developing rats exposed to 0.5% 
cholesterol diet during gestation, lactation and post weaning had a 
significantly larger left cortex and the cholesterol and protein concentration of 
the left cortex (mg/g) were also increased. Higher exposure to exogenous 
cholesterol during development appears to influence cortex size and the 
concentration of cholesterol and total protein per gram of brain. Further 
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studies need to be done to evaluate the effect of dietary cholesterol and 
increased brain cholesterol on rat behavior and nervous function. Ultimately, it 
needs to be seen if supplementing infant formulas with cholesterol has a 
positive effect on brain development in infants. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
51
References 
 
1. Chattopadhyay A, Paila YD. Lipid-protein interactions, regulation and 
dysfunction of brain cholesterol. Biochem Biophysl Res Commun 2007; 
354:627-33. 
2. Kurban S, Mehmetoglu I, Yilmaz G. Effect of diet oils on lipid levels of 
the brain of rats. Indian Journal of Clinical Biochemistry 2007;22:44-47. 
3. Liscum L, Underwood KW. Intracellular cholesterol transport and 
compartmentation.  J Biol Chem 1995;270:15443-6. 
4. Simons K, Ikonen E. How cells handle cholesterol. Science 
2000;290:1721-6. 
5. Chevallier F, Serougne C, Champarnaud G. Effect upon brain weight 
and cholesterol content of maintaining rats of various ages at constant 
weight. J Nutr 1975;105:1003-11. 
6. Bjorkhem I, Meaney S. Brain cholesterol: long secret life behind a 
barrier. Arterioscler  Thromb Vasc Biol 2004;24:806-15. 
7. Kinney HC, Brody BA, Kloman AS, Gilles FH. Sequence of central 
nervous system myelination in human infancy. II. Patterns of 
myelination in autopsied infants. J Neuropathol Exp Neurol 
1988;47:217-34. 
8. Snipes GJ, Suter U. Cholesterol and myelin. Subcell Biochem 
1997;28:173-204. 
 
 
52
9. Cuzner ML, Davison AN. The lipid composition of rat brain myelin and 
subcellular fractions during development. Biochem J 1968;106:29-34. 
10. Edmond J, Korsak RA, Morrow JW, Torok-Both G, Catlin DH. Dietary 
cholesterol and the origin of cholesterol in the brain of developing rats. 
J Nutr 1991;121:1323-30. 
11. Kris-Etherton PM, Layman DK, York PV, Frantz ID. The influence of 
early nutrition on the serum cholesterol of the adult rat. J Nutr 
1979;109:1244-57. 
12. Reiser R, Sidelman Z. Control of serum cholesterol homeostasis by 
cholesterol in the milk of the suckling rat. J Nutr 1972;102:1009-16. 
13. Bayley TM, Alasmi M, Thorkelson T, et al. Influence of formula versus 
breast milk on cholesterol synthesis rates in four-month-old infants. 
Pediatr  Res 1998;44:60-7. 
14. Boleman SL, Graf TL, Mersmann HJ, et al. Pigs fed cholesterol 
neonatally have increased cerebrum cholesterol as young adults. J 
Nutr 1998;128:2498-504. 
15. Clarenburg R, Chaikoff IL, Morris MD. Incorporation of injected 
cholesterol into the myelinating brain of the 17-day-old rabbit. J 
Neurochem 1963;10:135-43. 
16. Davison AN, Dobbing J, Morgan RS, Wright GP. The deposition and 
disposal of (4-14C) cholesterol in the brain of growing chickens. J 
Neurochem 1958;3:89-94. 
 
 
53
17. Dobbing J. The entry of cholesterol into rat brain during development. J 
Neurochem 1963;10:739-42. 
18. Serougne C, Chevallier F. Microscopic radioautography of adult rat 
brain cholesterol. Problem of the blood-brain barrier. Exp Neurol 
1974;44:1-9. 
19. Morris MD, Chaikoff IL. Concerning incorporation of labelled 
cholesterol, fed to the mothers, into brain cholesterol of 20-day-old 
suckling rats. J Neurochem 1961;8:226-9. 
20. Jurevics H, Morell P. Cholesterol for synthesis of myelin is made 
locally, not imported into brain. J Neurochem 1995;64:895-901. 
21. Lee AG. How lipids affect the activities of integral membrane proteins. 
Biochim  Biophys  Acta 2004;1666:62-87. 
22. Palsdottir H, Hunte C. Lipids in membrane protein structures. Biochim 
Biophys  Acta 2004;1666:2-18. 
23. Vance DE, Van den Bosch H. Cholesterol in the year 2000. Biochim 
Biophys Acta 2000;1529:1-8. 
24. Murray RK, Granner DK, Mayes PA, Rodwell VW. Harper's 
Biochemistry. 25th ed: McGraw-Hill Publishing Co, 1999. 
25. Dietschy JM, Turley SD. Control of cholesterol turnover in the mouse. J 
Biol Chem 2002;277:3801-4. 
26. Koenig SH. Cholesterol of myelin is the determinant of gray-white 
contrast in MRI of brain. Magn Reson Med 1991;20:285-91. 
 
 
54
27. Davison AN. Brain sterol metabolism. Adv Lipid Res 1965;3:171-96. 
28. Couerbe JP. Du Cerveau, conside´re´ sous le point du vue chimique et 
physiologique. Annales de Chimie et de Physique 1834;56:160-193. 
29. Bloch K, Berg BN, Rittenberg D. The biological conversion of 
cholesterol to cholic acid. J Biol Chem 1943;149:511-517. 
30. Waelsch H, Sperry WM, Stoyanoff VA. A study of the synthesis and 
deposition of lipids in brain and other tissues with deuterium as an 
indicator J Biol Chem 1940;135:291-296. 
31. Chobanian AV, Hollander W. Body cholesterol metabolism in man. I. 
The equilibration of serum and tissue cholesterol. J Clin Invest 
1962;41:1732-7. 
32. Morell P, Jurevics H. Origin of cholesterol in myelin. Neurochem Res 
1996;21:463-70. 
33. Dietschy JM, Turley SD. Cholesterol metabolism in the brain. Curr 
Opin  Lipidol 2001;12:105-12. 
34. Kabara JJ. A critical review of brain cholesterol metabolism. Prog Brain 
Res 1973;40:363-82. 
35. Pfrieger FW. Cholesterol homeostasis and function in neurons of the 
central nervous system. Cell Mol Life Sci 2003;60:1158-71. 
36. Sastry PS. Lipids of nervous tissue: composition and metabolism. Prog 
Lipid Res 1985;24:69-176. 
 
 
55
37. Lutjohann D, von Bergmann K. 24S-hydroxycholesterol: a marker of 
brain cholesterol metabolism. Pharmacopsychiatry 2003;36 Suppl 
2:S102-6. 
38. Papakostas GI, Ongur D, Iosifescu DV, Mischoulon D, Fava M. 
Cholesterol in mood and anxiety disorders: review of the literature and 
new hypotheses. Eur Neuropsychopharmacol 2004;14:135-42. 
39. Pucadyil TJ, Chattopadhyay A. Role of cholesterol in the function and 
organization of G-protein coupled receptors. Prog Lipid Res 
2006;45:295-333. 
40. Ohvo-Rekila H, Ramstedt B, Leppimaki P, Slotte JP. Cholesterol 
interactions with phospholipids in membranes. Prog Lipid Res 
2002;41:66-97. 
41. Saher G, Brugger B, Lappe-Siefke C, et al. High cholesterol level is 
essential for myelin membrane growth. Nat Neurosci 2005;8:468-75. 
42. Haines TH. Do sterols reduce proton and sodium leaks through lipid 
bilayers? Prog Lipid Res 2001;40:299-324. 
43. Brown DA, London E. Structure and function of sphingolipid- and 
cholesterol-rich membrane rafts. J Biol Chem 2000;275:17221-4. 
44. Simons K, Toomre D. Lipid rafts and signal transduction. Nat Rev Mol 
Cell Biol 2000;1:31-9. 
 
 
56
45. Diaz RS, Monreal J. Unusual low proton permeability of liposomes 
prepared from the endogenous myelin lipids. J Neurochem 
1994;62:2022-9. 
46. North P, Fleischer S. Alteration of synaptic membrane 
cholesterol/phospholipid ratio using a lipid transfer protein. Effect on 
gamma-aminobutyric acid uptake. J Biol Chem 1983;258:1242-53. 
47. Shouffani A, Kanner BI. Cholesterol is required for the reconstruction 
of the sodium- and chloride-coupled, gamma-aminobutyric acid 
transporter from rat brain. J Biological Chem 1990;265:6002-8. 
48. Guirland C, Zheng JQ. Membrane lipid rafts and their role in axon 
guidance. Adv Exp Med Biol 2007;621:144-55. 
49. Fredriksson R, Lagerstrom MC, Lundin L-G, Schioth HB. The G-
protein-coupled receptors in the human genome form five main 
families. Phylogenetic analysis, paralogon groups, and fingerprints. 
Mol  Pharmacol 2003;63:1256-72. 
50. Gaspar P, Cases O, Maroteaux L. The developmental role of 
serotonin: news from mouse molecular genetics. Nat Rev Neurosci 
2003;4:1002-12. 
51. Pucadyil TJ, Chattopadhyay A. Cholesterol modulates ligand binding 
and G-protein coupling to serotonin(1A) receptors from bovine 
hippocampus. Biochim  Biophys Acta 2004;1663:188-200. 
 
 
57
52. Lemke G. The molecular genetics of myelination: an update. Glia 
1993;7:263-71. 
53. Boison D, Stoffel W. Disruption of the compacted myelin sheath of 
axons of the central nervous system in proteolipid protein-deficient 
mice. Proc Nat Academy of Sciences of the United States of America 
1994;91:11709-13. 
54. Inoue Y, Nakamura R, Mikoshiba K, Tsukada Y. Fine structure of the 
central myelin sheath in the myelin deficient mutant Shiverer mouse, 
with special reference to the pattern of myelin formation by 
oligodendroglia. Brain Res 1981;219:85-94. 
55. Privat A, Jacque C, Bourre JM, Dupouey P, Baumann N. Absence of 
the major dense line in myelin of the mutant mouse "shiverer". 
Neurosci Lett 1979;12:107-12. 
56. Wells MA, Dittmer JC. A comprehensive study of the postnatal 
changes in the concentration of the lipids of developing rat brain. 
Biochemistry 1967;6:3169-75. 
57. Bourre JM, Clement M, Gerard D, Legrand R, Chaudiere J. Precursors 
for cholesterol synthesis (7-dehydrocholesterol, 7-dehydrodesmosterol, 
and desmosterol): cholesterol/7-dehydrocholesterol ratio as an index of 
development and aging in PNS but not in CNS. J Neurochem 
1990;54:1196-9. 
 
 
58
58. Kinney HC, Karthigasan J, Borenshteyn NI, Flax JD, Kirschner DA. 
Myelination in the developing human brain: biochemical correlates. 
Neurochem Res 1994;19:983-96. 
59. Hinse CH, Shah SN. The desmosterol reductase activity of rat brain 
during development. J Neurochem 1971;18:1989-98. 
60. De Chaves EI, Rusinol AE, Vance DE, Campenot RB, Vance JE. Role 
of lipoproteins in the delivery of lipids to axons during axonal 
regeneration. J Biol Chem 1997;272:30766-73. 
61. Fan QW, Yu W, Senda T, Yanagisawa K, Michikawa M. Cholesterol-
dependent modulation of tau phosphorylation in cultured neurons. J 
Neurochem 2001;76:391-400. 
62. Goritz C, Mauch DH, Pfrieger FW. Multiple mechanisms mediate 
cholesterol-induced synaptogenesis in a CNS neuron. Mol Cell 
Neurosci 2005;29:190-201. 
63. Handelmann GE, Boyles JK, Weisgraber KH, Mahley RW, Pitas RE. 
Effects of apolipoprotein E, beta-very low density lipoproteins, and 
cholesterol on the extension of neurites by rabbit dorsal root ganglion 
neurons in vitro. J Lipid Res 1992;33:1677-88. 
64. Mauch DH, Nagler K, Schumacher S, et al. CNS synaptogenesis 
promoted by glia-derived cholesterol. Science 2001;294:1354-7. 
 
 
59
65. Sakamoto H, Ukena K, Tsutsui K. Effects of progesterone synthesized 
de novo in the developing Purkinje cell on its dendritic growth and 
synaptogenesis. J Neurosci 2001;21:6221-32. 
66. Koudinov AR, Koudinova NV. Essential role for cholesterol in synaptic 
plasticity and neuronal degeneration. FASEB J 2001;15:1858-60. 
67. Volpe JJ, Goldberg RI, Bhat NR. Cholesterol biosynthesis and its 
regulation in dissociated cell cultures of fetal rat brain: developmental 
changes and the role of 3-hydroxy-3-methylglutaryl coenzyme A 
reductase. J Neurochem 1985;45:536-43. 
68. Vance JE, Hayashi H, Karten B. Cholesterol homeostasis in neurons 
and glial cells. Semin Cell Dev Biol 2005;16:193-212. 
69. Jira PE, Waterham HR, Wanders RJ, Smeitink JA, Sengers RC, 
Wevers RA. Smith-Lemli-Opitz syndrome and the DHCR7 gene. Ann 
Hum Genet 2003;67:269-80. 
70. Tint GS, Batta AK, Xu G, et al. The Smith-Lemli-Opitz syndrome: a 
potentially fatal birth defect caused by a block in the last enzymatic 
step in cholesterol biosynthesis. Subcell Biochem 1997;28:117-44. 
71. Smith DW, Lemli L, Opitz JM. A newly recognized syndrome of 
multiple congenital anomalies.  J  Pediatr 1964;64:210-7. 
72. Marcos J, Shackleton CH, Buddhikot MM, Porter FD, Watson GL. 
Cholesterol biosynthesis from birth to adulthood in a mouse model for 
 
 
60
7-dehydrosterol reductase deficiency (Smith-Lemli-Opitz syndrome). 
Steroids 2007;72:802-8. 
73. Boersma ER, Offringa PJ, Muskiet FA, Chase WM, Simmons IJ. 
Vitamin E, lipid fractions, and fatty acid composition of colostrum, 
transitional milk, and mature milk: an international comparative study. 
Am J Clin Nutr 1991;53:1197-204. 
74. Picciano MF. Nutrient composition of human milk. Pediatr Clin North 
Am 2001;48:53-67. 
75. Jensen RG, Ferris AM, Lammi-Keefe CJ. Lipids in human milk and 
infant formulas. Annu  Rev Nutr 1992;12:417-41. 
76. Lammi-Keefe CJ, Ferris AM, Jensen RG. Changes in human milk at 
0600, 1000, 1400, 1800, and 2200 h. J Pediatr Gastroenterol Nutr 
1990;11:83-8. 
77. Clark RM, Hundrieser KE. Changes in cholesteryl esters of human milk 
with total milk lipid. J Pediatr Gastroenterol Nutr 1989;9:347-50. 
78. Morrow-Tlucak M, Haude RH, Ernhart CB. Breastfeeding and cognitive 
development in the first 2 years of life. Socl Sci Med  1988;26:635-9. 
79. Ounsted M, Moar VA, Cockburn J, Redman CW. Factors associated 
with the intellectual ability of children born to women with high risk 
pregnancies. Br Med J (Clin Res ed.) 1984;288:1038-41. 
80. Pollock JI. Mother's choice to provide breast milk and developmental 
outcome. Arch  Dis Child 1989;64:763-4. 
 
 
61
81. Rogan WJ, Gladen BC. Breast-feeding and cognitive development. 
Early Hum Dev 1993;31:181-93. 
82. Anderson JW, Johnstone BM, Remley DT. Breast-feeding and 
cognitive development: a meta-analysis. Am J Clin Nutr 1999;70:525-
35. 
83. Angelsen NK, Vik T, Jacobsen G, Bakketeig LS. Breast feeding and 
cognitive development at age 1 and 5 years. Arch Dis Child 
2001;85:183-8. 
84. Carlson SE, House SG. Oral and intraperitoneal administration of N-
acetylneuraminic acid: effect on rat cerebral and cerebellar N-
acetylneuraminic acid. J Nutr 1986;116:881-6. 
85. Haque ZU, Mozaffar Z. Importance of dietary cholesterol for the 
maturation of mouse brain myelin. Biosci Biotechnol Biochem 
1992;56:1351-4. 
86. Schoknecht PA, Ebner S, Pond WG, et al. Dietary cholesterol 
supplementation improves growth and behavioral response of pigs 
selected for genetically high and low serum cholesterol. J Nutr 
1994;124:305-14. 
87. Lucas A, Morley R, Cole TJ, Lister G, Leeson-Payne C. Breast milk 
and subsequent intelligence quotient in children born preterm. Lancet 
1992;339:261-4. 
 
 
62
88. Morley R, Cole TJ, Powell R, Lucas A. Mother's choice to provide 
breast milk and developmental outcome. Arch Dis Child 1988;63:1382-
5. 
89. Innis SM. Essential fatty acids in infant nutrition: lessons and 
limitations from animal studies in relation to studies on infant fatty acid 
requirements. Am J Clin Nutr 2000;71:238S-44S. 
 
 
 
